HMG (High Mobility Group)

What it is

The abbreviation 'HMG' encompasses three distinct biological entities in the reviewed literature: 1. HIGH MOBILITY GROUP (HMG) PROTEINS (chromatin/nuclear proteins): HMG proteins are a superfamily of abundant, ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber. The superfamily is divided into three families (HMGA, HMGB, HMGN) and can be further classified by whether they bind DNA in a sequence-specific or sequence-independent manner. HMG-box domains mediate DNA binding; both types bind non-B-type DNA structures (bent, kinked, unwound) with high affinity and are involved in protein-protein interactions. HMG proteins are considered architectural elements of chromatin that dynamically modulate DNA-dependent processes. HMG-14 and HMG-17 (HMGN family) specifically bind nucleosome core particles, unfold higher-order chromatin structure, and enhance transcription and replication potential of chromatin. HMG-I(Y) proteins preferentially recognize the narrow minor groove of A·T-rich sequences of B-form DNA and function as structural transcription factors for mammalian genes; they are substrates for Cdc2 kinase, which phosphorylates their DNA-binding domains. HMG-1 (HMGB1) activates p53 DNA binding and enhances transcription factor assembly on DNA. TOX is an HMG-box transcription factor implicated in CD8 T cell exhaustion. The SOX family proteins contain a single sequence-specific HMG box and regulate development and differentiation. 2. HUMAN MENOPAUSAL GONADOTROPIN (hMG): hMG (menotropins) is a gonadotropin preparation containing FSH and LH activity used for ovulation induction and controlled ovarian stimulation in assisted reproduction. It stimulates follicular development and ovulation. Highly purified hMG (HP-hMG) contains human chorionic gonadotropin (hCG) constituting most of its LH-like activity. 3. HMG-CoA REDUCTASE / INHIBITORS (statins): HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase) catalyzes the rate-limiting step in cholesterol and isoprenoid biosynthesis — the four-electron oxidoreduction of HMG-CoA to mevalonate. The enzyme is extensively regulated at transcriptional, translational, and post-translational levels and is anchored to the endoplasmic reticulum in eukaryotes. HMG-CoA reductase inhibitors (statins) inhibit cholesterol synthesis and have additional pleiotropic cardiovascular effects including modulation of endothelial function, inflammation, thrombosis, and immune response.

Class: NOTE: The abbreviation 'HMG' is highly ambiguous across the provided abstracts and refers to at least three entirely distinct entities: (1) High Mobility Group nuclear/chromatin proteins (a superfamily of non-histone chromosomal proteins), (2) Human Menopausal Gonadotropin (a gonadotropin hormone preparation used in assisted reproduction), and (3) HMG-CoA reductase and its inhibitors (statins, an enzyme and drug class involved in cholesterol biosynthesis). This record covers all three based on the provided literature. Users and reviewers must specify which 'HMG' entity they are querying.

What it's studied for

• HMG proteins — Chromatin structure regulation and transcriptional enhancement In vitro only
  • HMG-14 and HMG-17 contain distinct functional domains: a nucleosomal binding domain and a C-terminal transcriptional enhancement domain; deletion of C-terminal residues reduces transcriptional enhancement from chromatin templates. PMID 8524231 Trieschmann et al., Mol Cell Biol (1995)
  • HMG-14/17 proteins segregate into distinct nuclear domains; nucleosomes containing HMG-17 are clustered in groups averaging six contiguous HMG-17-containing nucleosomes; proposed to unfold higher-order chromatin structure. PMID 9417927 Postnikov et al., J Mol Biol (1997)
  • PCAF specifically acetylates HMG-17 at lysine 2, reducing its affinity for nucleosome cores; HMG-14/17 binding to nucleosomes inhibits PCAF-mediated acetylation of histone H3. PMID 10207070 Herrera et al., Mol Cell Biol (1999)
  • HMG-17 colocalizes with sites of active transcription; its association with chromatin is dynamic and redistributes to interchromatin granule clusters upon transcriptional inhibition. PMID 9843505 Hock et al., EMBO J (1998)
  • Hydroxyl radical footprinting maps HMG-14/17 binding sites on nucleosome cores; proteins bridge two adjacent DNA strands near the nucleosomal dyad axis. PMID 8107104 Alfonso et al., J Mol Biol (1994)
• HMG proteins — Role in development, differentiation, and disease Mixed
  • Review: HMG protein expression is developmentally regulated; changes in HMG levels alter cellular phenotype and can lead to developmental abnormalities and disease in humans and genetically modified mice. PMID 17169561 Hock et al., Trends Cell Biol (2007)
  • Review: HMG-I, -Y, and -I-C are expressed at high levels during embryogenesis and are derepressed in neoplastic cells; HMG-I and Y participate in enhanceosome formation; HMG-I-C has a role in adipogenesis. PMID 11485207 Liu et al., Immunol Res (2001)
  • HMG-17 acts as a molecular switch regulating homeodomain transcriptional activity via Wnt/beta-catenin signaling; HMG-17 homozygous knockout mice exhibit early embryonic lethality. PMID 18045789 Amen et al., Nucleic Acids Res (2008)
• HMG-I/Y — Role in cancer / neoplastic transformation Mixed
  • HMG-I/Y proteins are increased in human breast cancer cell lines vs. normal breast cells; antisense ribozyme knockdown inhibits transformation; increased HMG-I expression in normal breast cells leads to transformation, suggesting an oncogenic role. PMID 12002338 Dolde et al., Breast Cancer Res Treat (2002)
  • HMG-I(Y) expression is increased in metastatic breast cancer cells and is dynamically regulated by heregulin-erbB signaling and extracellular matrix; HMG-I(Y) specifically binds base-unpairing regions of matrix attachment sequences. PMID 10582687 Liu et al., Cancer Res (1999)
  • Chromosomal translocations involving HMG-I(Y) genes are observed in numerous human tumors; chimeric fusion proteins containing HMG-I(Y) A·T-hook motifs retain AT-rich DNA-binding properties in vitro. PMID 10347218 Banks et al., J Biol Chem (1999)
• HMG-1 — Activation of p53 DNA binding and transcription In vitro only
  • HMG-1 purified from HeLa nuclear extracts enhances p53 DNA binding in vitro, interacts directly with p53, and increases p53-mediated transactivation in transient transfection assays; proposed to act via structural change in target DNA. PMID 9472015 Jayaraman et al., Genes Dev (1998)
• HMG proteins — Stimulation of HIV-1 and avian sarcoma virus DNA integration in vitro In vitro only
  • HMG-I(Y) most closely replicates in vivo features of concerted HIV-1 and ASV integration in a reconstituted in vitro system; stimulation requires the DNA-binding domain of HMG-I(Y). PMID 10074149 Hindmarsh et al., J Virol (1999)
• HMG-CoA reductase expression — Breast cancer prognosis and tamoxifen response prediction Human observational
  • High HMG-CoAR expression in 511 breast cancers is associated with smaller tumor size, low histological grade, low Ki67, ER-positivity, and high p27 expression (less aggressive phenotype); obesity significantly associated with high HMG-CoAR expression. PMID 18528862 Borgquist et al., Int J Cancer (2008)
  • HMG-CoAR mRNA expression predicts recurrence-free survival in tamoxifen-treated patients; HMG-CoAR-positive tumors show improved RFS with adjuvant tamoxifen (HR=0.67, p=0.010); HMG-CoAR expression decreased in tamoxifen-resistant cells. PMID 21281480 Brennan et al., Breast Cancer Res (2011)
• HMG-CoA reductase inhibitors (statins) — Reduction of cardiovascular risk / coronary artery disease Human RCT
  • Review: HMG-CoA reductase inhibitors significantly reduce CAD events and CAD-related mortality; secondary prevention is cost-effective; primary prevention cost-effective depending on CAD risk and drug dosage. PMID 14727930 McCabe, Am J Cardiovasc Drugs (2003)
  • Review: HMG-CoA reductase inhibitors reduce cardiovascular events via multiple nonlipid mechanisms including improvement of endothelial function, anti-inflammatory effects, anti-thrombotic effects, and immune modulation. PMID 14728000 Rosenson, Am J Cardiovasc Drugs (2001)
  • Review: HMG-CoA reductase inhibitors may prevent accelerated graft atherosclerosis in heart transplant patients; concurrent use with cyclosporine increases risk of musculoskeletal complications due to pharmacokinetic interaction. PMID 9101013 Southworth & Mauro, Ann Pharmacother (1997)
• Human menopausal gonadotropin (hMG) — Ovulation induction and controlled ovarian stimulation for IVF/ICSI Human RCT
  • RCT of 280 patients: no significant difference in ongoing pregnancy rate between hp-hMG and rFSH in GnRH antagonist cycles (35.0% vs 32.1%); rFSH yielded more oocytes; hp-hMG produced higher estradiol, rFSH higher progesterone at end of stimulation. PMID 18583332 Bosch et al., Hum Reprod (2008)
  • HP-hMG produced significantly higher implantation (20.0% vs 8.1%) and pregnancy rates (47.2% vs 19.4%) compared to traditional hMG in IVF; proportion of top-quality embryos significantly higher with HP-hMG. PMID 20500109 Orvieto et al., Gynecol Endocrinol (2010)
  • In patients with high basal FSH/LH ratio, HMG produced significantly higher top-quality embryos, implantation (27.9% vs 5.3%) and clinical pregnancy rates (44.4% vs 11.1%) compared to rFSH. PMID 19192340 Orvieto et al., Reprod Biomed Online (2009)
  • RCT: Sequential CC/hMG regimen produced significantly higher pregnancy rate (26.7%) vs hMG alone (6.7%) with significantly lower gonadotropin dose in clomiphene-resistant women. PMID 23080548 Abdelazim & Makhlouf, Arch Gynecol Obstet (2013)
  • Retrospective cohort (n=5901 FET cycles): letrozole or letrozole+HMG showed higher clinical pregnancy rates than hMG alone (52.07%, 52.26% vs 47.02%); letrozole associated with lower miscarriage and ectopic pregnancy rates. PMID 31840707 Lin et al., Drug Des Devel Ther (2019)
• Human menopausal gonadotropin (hMG) — Endometrial preparation for frozen-thawed embryo transfer (FET) Human observational
  • Retrospective analysis (n=5070 FET cycles): modified hMG stimulated group had significantly higher clinical pregnancy rates and live birth rates compared to natural cycling, HRT, and letrozole groups. PMID 29676585 Huang et al., Gynecol Endocrinol (2018)
• Human menopausal gonadotropin (hMG) — Superovulation in cattle Animal studies only
  • hMG at 900 IU produced significantly greater number of recovered ova/embryos vs FSH in Japanese Black cattle; 600 IU for 3 days was sufficient for superovulation; FSH-treated cows produced significantly more unfertilized ova. PMID 8720060 Sugano et al., J Vet Med Sci (1995)
• HMG — Targeted siRNA delivery to alveolar macrophages (asthma model) Animal studies only
  • HMG protein (HMGB1) used as a targeting ligand binding TLR4 and RAGE on activated macrophages for siRNA delivery via ternary complexes (siRNA/HMG/oligoarginine micelles); intratracheal administration reduced Chil3/Chil4 expression and suppressed asthma symptoms in a mouse model. PMID 31840707 Choi et al., Nanoscale (2020)
• HMG box domain proteins — Role in T cell development and exhaustion Mixed
  • Review: TOX, an HMG-box transcription factor, is a central player in CD8 T cell exhaustion; HMG-box proteins stabilize kinked or bent DNA; diverse biological mechanisms discussed for HMG-box proteins in immune cell processes. PMID 40746547 Hogan et al., Front Immunol (2025)
  • TOX defines a novel conserved subfamily of HMG-box proteins involved in T cell development; highly conserved in humans, mice, pufferfish, and mosquito; three additional family members identified (TOX2, TOX3, TOX4) with distinct tissue expression patterns. PMID 12697058 O'Flaherty & Kaye, BMC Genomics (2003)
  • Review: HMG box proteins divided into HMG/UBF (non-sequence specific, multiple HMG boxes) and TCF/SOX (sequence specific, single HMG box) subfamilies; both subfamilies have roles in T cell lineage commitment and differentiation. PMID 8209398 Oosterwegel et al., Thymus (1993)

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.